Install
Clinical Trials (Phases I–IV)
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Clinical Trials (Phases I–IV)
Ebola Vaccine Undergoes Testing Against Bundibugyo Virus
8+ hour, 3+ min ago (513+ words) Scientists are preparing to test vaccine candidates against the Bundibugyo virus in the Democratic Republic of the Congo (DRC). The Phase 2/3 clinical trial, expected to begin in the coming weeks subject to ethical and regulatory approval, will assess the safety…...
Ocular Hypertension Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players Wheeling the Therapeutics Landscape
3+ hour, 52+ min ago (97+ words) The Ocular Hypertension Clinical Trial analysis report delivers important insights into ongoing research on 50 pipeline Ocular Hypertension Drugs clinical strategies upcoming therapeutics and commercial analysis Albany US October 13 2026 DelveInsight s Ocular Hypertension Pipeline Insight 2026 report provides... Ocular Hypertension Clinical Trial…...
AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA
6+ hour, 56+ min ago (604+ words) Ophthalmology Times...
BMY Reports Mixed Phase III Trial Results, Stock Down
12+ hour, 26+ min ago (835+ words) Bristol Myers Squibb BMY announced mixed phase III results for admilparant, its investigational treatment for idiopathic pulmonary fibrosis (IPF). While BMY stock opened higher, it reversed course and ended trading down 2.6% on Oct. 12. Shares of Bristol Myers have gained 6.8% year…...
Glaukos reports positive 3-year, phase 3 Epioxa clinical outcomes
9+ hour, 50+ min ago (330+ words) Glaukos Corporation recently reported positive 3-year data from the long-term phase 3 extension study evaluating the durability, visual outcomes, and safety of Epioxa HD / Epioxa (riboflavin 5–phosphate ophthalmic solution 0.239% / 0.177%) for the treatment of keratoconus (KC). Epioxa is the first and only…...
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
18+ hour, 1+ min ago (512+ words) Qualcomm Statement on Trial Verdict Win The findings include a pre-specified subgroup analysis for ralinepag and a post-hoc disease progression analysis for nebulized treprostinil. A pre-specified subgroup analysis from the phase 3 ADVANCE OUTCOMES study showed that ralinepag reduced the risk…...
Inhibrx's OX40 agonist nearly doubles response rate versus Keytruda alone in head and neck cancer
6+ day, 9+ hour ago (668+ words) AllSci is an AI-grounded scientific knowledge platform. It aggregates the global scientific literature, patents, grants and trials, atomizes them into hypotheses, questions, results and claims, links everything to canonical entity identifiers, and answers questions through AERIS with evidence-grounded, sentence-level citations....
Targeting the RUNX1 gene helps reduce severe skin fibrosis
11+ hour, 23+ min ago (264+ words) Skin fibrosis includes hypertrophic scar (HTS), keloid scar (KS), and systemic sclerosis (SSc). These conditions share persistent fibroblast activation, excessive extracellular matrix (ECM) deposition, and progressive skin remodeling. Targeting the RUNX1 gene helps reduce severe skin fibrosis Skin fibrosis includes hypertrophic…...
āshibio Presents Biomarker Data Supporting Vantictumab Development for ADO2 and a Prevalence Estimate of CLCN7-Related ADO2 of 1–4 per 20,000 Individuals
11+ hour, 21+ min ago (159+ words) – Biomarker data demonstrate osteoclast activation at low doses of vantictumab without impacting osteoblast activity, strengthening therapeutic rationale for the treatment of autosomal dominant osteopetrosis type 2 (ADO2) – Analysis of international genetic database is consistent with prior prevalence estimates and suggests a substantial…...
BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer
11+ hour, 27+ min ago (600+ words) The phase 2/3 AHEAD-MERIT trial will continue to assess overall survival among patients who received BNT113 plus pembrolizumab for head and neck cancer. The investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran) in combination with pembrolizumab (Keytruda) did not demonstrate a statistically significant improvement…...